Introduction
============

*Pseudomonas aeruginosa* is a commonly occurring nosocomial Gram-negative pathogen that is often associated with antibiotic resistant phenotypes, a profile that has been linked to therapeutic failure ([@b7-idr-1-051]; [@b16-idr-1-051]). This organism can confer multiple mechanisms of resistance, including β-lactamase production, expression of efflux pumps, and reduction of its outer-membrane (porin) permeability ([@b4-idr-1-051]; [@b18-idr-1-051]; [@b23-idr-1-051]). While resistance due to these mechanisms may be expressed concurrently, the presence of efflux pumps are an important singular determinant of multi-drug resistance ([@b4-idr-1-051]; [@b5-idr-1-051]; [@b17-idr-1-051]; [@b23-idr-1-051]; [@b24-idr-1-051]). There exist in *P. aeruginosa* naturally occurring multidrug-efflux (Mex) pumps that consist of three components: 1) a cytoplasmic-membrane associated the resistance-nodulation-division (RND) transmembrane protein transporter (eg, MexB, MexY), 2) an outer membrane gated channel (eg, OprM, OprN, OprJ), and 3) a periplasmic membrane fusion lipoprotein or pump assembly (eg, MexA, MexX) linking the two membrane bound components ([@b9-idr-1-051]). Four predominant Mex efflux systems have been reported: MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM ([@b1-idr-1-051]; [@b17-idr-1-051]; [@b22-idr-1-051]; [@b23-idr-1-051]); each has a preferential set of antimicrobial agent substrates. For instance, MexXY-OprM is capable of extruding cefepime, cefotaxime, levofloxacin, ciprofloxacin, amikacin, gentamicin, tobramycin, erythromycin, tetracycline, and meropenem ([@b1-idr-1-051]; [@b14-idr-1-051]; [@b19-idr-1-051]). The overexpression of MexXY in *P. aeruginosa* isolates was initially reported by [@b26-idr-1-051] and then by [@b27-idr-1-051] as the mechanism responsible for fluoroquinolone and aminoglycosides resistance, respectively.

Cefepime and ceftazidime are two cephalosporins used clinically against *P. aeruginosa.* Minimum inhibitory concentrations (MICs) and percent susceptibility for these agents are generally similar ([@b6-idr-1-051]; [@b11-idr-1-051]); however, in 2006, Hocquet et al reported the overexpression of the MexXY-OprM efflux pump as a major mechanism for *P. aeruginosa* isolates that were cefepime resistant/ceftazidime susceptible in two French hospitals ([@b8-idr-1-051]). The MIC~50~ for cefepime was 2-fold higher than ceftazidime in this phenotype. While cefepime is a substrate for MexXY-OprM, ceftazidime does not appear to be affected by this type of efflux pump ([@b1-idr-1-051]).

At our 810 bed inner city teaching hospital, cefepime is widely used for empiric and definitive therapy of *P. aeruginosa*. After the formulary replacement of ceftazidime with cefepime in 2000, *P. aeruginosa* susceptibility to cefepime appeared to decline while the percent susceptible to ceftazidime remained stable over the next several years. Initially, we attributed this to errors in automated testing systems since it had been previously reported that some systems over report resistance for cefepime ([@b3-idr-1-051]; [@b10-idr-1-051]; [@b20-idr-1-051]). Recently, however, we have detected *P. aeruginosa* strains that appear to be resistant to all β-lactams except ceftazidime. Upon further evaluation, these recent isolates were susceptible or intermediate to ceftazidime, non-susceptible to cefepime, and had cefepime MICs that were at least 2-fold greater than ceftazidime. As a result of these observations we sought to determine if one potential explanation for this phenotype profile was the overexpression of the MexXY-OprM efflux pump.

Materials and methods
=====================

*P. aeruginosa* clinical isolates collected at Hartford Hospital during an institutional survey in 2005--2006 were selected for analysis. We randomly chose 15 nonduplicate *P. aeruginosa* that were susceptible or intermediate to ceftazidime, non-susceptible to cefepime, and had cefepime MICs that were at least 2-fold greater than that of ceftazidime. Most clinical isolates (n = 9) were from respiratory specimens; 6 of the 9 were obtained from patients diagnosed with ventilator-associated pneumonia. The remaining isolates were collected from the urinary tract and wound samples. Cefepime and ceftazidime MICs were determined by E-Test^®^ (AB Biodisk, Solna, Sweden) in duplicate and the mean values are reported.

Pulsed-field gel electrophoresis
--------------------------------

Clonality was assessed by means of pulsed-field gel electrophoresis (PFGE). Chromosomal DNA was prepared by the method of Matushek et al ([@b15-idr-1-051]), digested with XbaI, and separated by electrophoresis on a CHEF Mapper apparatus (BioRad Laboratories, Richmond, CA) at a voltage of 6 V/cm at 14 °C for 21 h, with pulse times linearly ramped from 1 to 25s. Strain relatedness was determined according to the criteria by Tenover et al ([@b25-idr-1-051]).

Isolation of total RNA
----------------------

Strains were inoculated in 2 ml calcium-adjusted Mueller Hinton broth (CaMHB) and grown overnight at 35 °C. Strains were diluted 1:1000 in CaMHB and cultures grown to an absorbance at 600 nm of 0.3 (corresponding to logarithmic phase). A 1.8 ml aliquot of this culture was added to 3.6 ml of RNA easy bacteria protect solution (Qiagen, Valencia, CA) and total RNA was isolated using the Qiagen RNeasy kit (Qiagen). Residual DNA was eliminated by an on-column DNAse digestion using the RNAse-free DNase set (Qiagen), and the RNA was resuspended in 30 μl of RNAse-free H~2~O.

Synthesis of cDNA for reverse transcriptase-polymerase chain reaction (RT-PCR)
------------------------------------------------------------------------------

Reverse transcription to cDNA was performed using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN) with random hexamers (60 μM) as described in depth by the manufacturer's instructions. The initial reaction mixture contained 2 μg of total RNA, which was subsequently divided into two aliquots. Reverse transcriptase was added to one aliquot, while the other aliquot served as a negative control to detect any residual genomic DNA in the RNA preparation. The cDNAs were stored at −20 °C until further analyses.

### RT-PCR analysis

Expression of the MexXY-OprM operon was assessed by quantitative RT-PCR with specific primers to determine the transcript levels of the gene *mexY* ([@b8-idr-1-051]) as previously described. A LightCycler^®^ 2.0 RT-PCR machine (Roche, software version 3.5) was used for the quantification of cDNA. Duplicate PCR reactions were performed using the LightCycler^®^ FastStart DNA Master ^PLUS^ SYBR Green I kit (Roche) according to manufacturer's instructions. A final concentration of 10% DMSO and 100 ng cDNA was used in a total volume of 20 μl for each reaction. After a 10 min activation of the Taq polymerase at 95 °C, 40 cycles of 15s at 95 °C, 5s at 62 °C, 12s at 72 °C were performed. A melt curve was run at the end of 40 cycles to test for the presence of a unique PCR reaction product.

The isogenic strains PAO1 (PAM1020, wild-type efflux expression) ([@b13-idr-1-051]) and PAM1323 (MexXY-OprM overexpressed) (gifts from O. Lomovskaya, Mpex Pharmaceuticals) served as controls and were analyzed in parallel with the clinical strains. The housekeeping gene, *rpoD* (sigma factor of RNA polymerase) ([@b21-idr-1-051]), served as the internal standard to correct for variations in the amount of starting template material. The threshold cycle (Ct) of each sample, which identified the cycle number during PCR when fluorescence exceeded a threshold value, was determined by the software, and the relative expression of *mexY* was assessed using the ΔΔCt method, as described previously ([@b12-idr-1-051]). The results represent relative expression levels (fold change) for a given target gene in the tested isolates compared to the PAO1 wild-type strain. Additionally, three clinical strains, having the same/similar MICs to both cefepime and ceftazidime, were used as efflux controls and showed mRNA transcript levels of *mexY* very close to that of PAO1 (0.8 times). The gain-of-efflux control strain demonstrated increased expression of *mexY* (26.2 times). A specific mRNA level of *mexY* greater than 4 times that of the wild-type susceptible strain PAO1 was considered to be a MexXY overproducer.

Results
=======

After the introduction and exclusive use of cefepime in 2000, our *P. aeruginosa* susceptibility as noted by the institutional antibiogram has been relatively constant for ceftazidime but appeared to drop for cefepime ([Table 1](#t1-idr-1-051){ref-type="table"}).

The cefepime/ceftazidime MIC ratio of the studied isolates ranged from 2.7 to ≥32 ([Table 2](#t2-idr-1-051){ref-type="table"}). As determined by PFGE, ten of the fifteen isolates clustered into three clonal groups. Group 1 consisted of the closely related isolates, PSA766 and 987 (2-band difference); Group 2 consisted of the indistinguishable PSA828, 882, and 782, and the closely-related PSA805 (2-band difference), and Group 3 consisted of the indistinguishable PSA814, 859, and 808, and the closely-related PSA855 (2-band difference). The five remaining isolates were unique pulsotypes.

In contrast to the dually susceptible control isolates, which showed no appreciable increase in *mexY* transcript levels, thirteen of the 15 isolates (87%) exhibited a marked increased in *mexY* gene expression levels (from 5.8- to 40.8-fold) relative to the reference wild-type susceptible strain PAO1 ([Table 2](#t2-idr-1-051){ref-type="table"}). The two clinical isolates that did not appear to show overexpression are designated as PSA784 and PSA831. While *mexY* overexpression was noted in the majority of these isolates, this was poorly correlated to the cefepime/ceftazidime MIC ratio. For example, while isolates PSA859 and PSA808 expressed high levels of *mexY* (21.3- and 34.3-fold higher than those observed in PAO1), their MIC ratios were 2.7 and 4.0, respectively. Moreover while PSA808 and PSA831 had the same cefepime/ceftazidime MIC ratio, PSA808 demonstrated high *mexY* expression (31.8-fold more than PAO1), while PSA831 did not.

Additionally, many of the MexY positive strains were multi-drug resistant. All 13 of these strains were resistant to ciprofloxacin and levofloxacin with the majority of MICs \>32 μg/ml. Forty-six percent (6/13) were meropenem nonsusceptible (1 intermediate, 5 resistant) and 1/13 (8%) was piperacillin-tazobactam resistant (MIC \> 256 μg/ml). Aminoglycoside MIC data were available for only 9 isolates, 8 of which were MexY positive: 5/8 were gentamicin resistant, 3/8 were resistant to tobramycin.

Together these data suggest that while the overexpression of the MexXY-OprM efflux pump may play an important role in our noted cefepime and ceftazidime MIC discordance, other currently unidentified mechanisms appear are contribute this phenotype profile.

Discussion
==========

To our knowledge, these are the first US derived data set to suggest that the MexXY-OprM efflux pump is a contributory factor for the observed discordant susceptibility profile between cefepime and ceftazidime in *P. aeruginosa.* Our results also confirm that the discordant MICs observed between cefepime and ceftazidime are not simply attributable to errors in the automated susceptibility systems but in fact, occur at least in part from *mexY* gene overexpression.

The majority of the *P. aeruginosa* isolates analyzed in this study over expressed the MexXY-OprM efflux pump. The degree of *mexY* gene overexpression and variability was similar between our study (5.8--40.8-fold) and that of [@b8-idr-1-051] (4.0--39.0-fold). Some of our clinical isolates also displayed resistance to meropenem, ciprofloxacin, levofloxacin, gentamicin and tobramycin, all of which are known to be MexXY-OprM substrates ([@b1-idr-1-051]; [@b14-idr-1-051]; [@b19-idr-1-051]).

The poor correlation between the cefepime/ceftazidime MIC ratio and the overexpression of *mexY* may be explained by the presence of other resistance mechanisms (ie, β-lactamases, outer-membrane proteins and/or other types of efflux. While studies to fully elucidate other possible mechanisms were not undertaken, the production of a β-lactamase, OXA-31, has been reported to also result in a cefepime resistant/ceftazidime susceptible phenotype in *P. aeruginosa* ([@b2-idr-1-051]). Double efflux pumps (MexAB-OprM and MexXY-OprM) have also been identified in some strains of *P. aeruginosa* that were resistant to meropenem and cefepime but susceptible to ceftazidime ([@b19-idr-1-051]).

Currently, the true prevalence of MexXY-OprM expressing *P. aeruginosa* is unknown at our hospital, so these data, along with declining cefepime susceptibilities have prompted us to empirically use higher cefepime dosages based on pharmacodynamics (eg, 2 g every 8 hours as prolonged infusions) or choose alternative antibiotics (ie, piperacillin/tazobactam). Additionally, the use of ceftazidime as definitive therapy for ceftazidime susceptible/cefepime non-susceptible *P. aeruginosa* has been considered.

In conclusion, our observation of MIC discordance between cefepime and ceftazidime in *P. aeruginosa* appears in part to be due to the overexpression of the MexXY-OprM efflux pump. Additional studies are required to fully elucidate the mechanism(s) responsible for this atypical phenotypic profile in *P. aeruginosa*.
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###### 

Hartford Hospital susceptibility for *Pseudomonas aeruginosa* to cefepime and ceftazidime from the year of cefepime formulary introduction to present

  **Year Collected**   **\# isolates[\*](#tfn2-idr-1-051){ref-type="table-fn"}**   **Susceptibility (%)**   **Difference (%)**   
  -------------------- ----------------------------------------------------------- ------------------------ -------------------- ----
  2000                 945                                                         77                       81                   4
  2001                 1041                                                        74                       87                   13
  2002                 1022                                                        75                       85                   10
  2003                 900                                                         74                       82                   8
  2004                 1207                                                        72                       81                   9
  2005                 1400                                                        65                       77                   12
  2006                 1256                                                        69                       82                   13

**Note:**

Isolates collected hospital-wide.

###### 

Results of MICs, PFGE, relative expression of *mexY* in *Pseudomonas aeruginosa* expressing the cefepime resistant/ceftazidime nonresistant phenotype

  **Strain ID**                                        **PFGE[^a^](#tfn5-idr-1-051){ref-type="table-fn"}**   **MIC (μg/ml)**   **FEP/CAZ MIC ratio**   **Specific mRNA level[^b^](#tfn6-idr-1-051){ref-type="table-fn"}**   ***mexY*Overexpression[^c^](#tfn7-idr-1-051){ref-type="table-fn"}**   
  ---------------------------------------------------- ----------------------------------------------------- ----------------- ----------------------- -------------------------------------------------------------------- --------------------------------------------------------------------- ----
  Wild-type efflux strain PAO1                         --                                                    1.5               1.25                    1.20                                                                 1.0                                                                   
  Susceptible clinical strains (n = 3)                 --                                                    1.5--3            1.5--3                  1.0--1.5                                                             0.8                                                                   
  Gain-of-efflux strain PAM 1323                       --                                                    7                 1.25                    5.60                                                                 26.2                                                                  \+
  PSA 766                                              NPSA1                                                 24                8                       3.00                                                                 5.8                                                                   \+
  PSA 987                                              NPSA1a                                                32                8                       4.00                                                                 5.9                                                                   \+
  PSA 828                                              NPSA2                                                 16                3                       5.33                                                                 11.2                                                                  \+
  PSA 882                                              NPSA2                                                 32                6                       5.33                                                                 7.0                                                                   \+
  PSA 782                                              NPSA2                                                 24                4                       6.00                                                                 11.8                                                                  \+
  PSA 805                                              NPSA2a                                                24                6                       4.00                                                                 6.8                                                                   \+
  PSA 814                                              NPSA3                                                 128               12                      10.67                                                                40.8                                                                  \+
  PSA 859                                              NPSA3                                                 32                8                       4.00                                                                 21.3                                                                  \+
  PSA 808                                              NPSA3                                                 16                6                       2.67                                                                 31.8                                                                  \+
  PSA 855                                              NPSA3a                                                24                6                       4.00                                                                 22.8                                                                  \+
  PSA 820                                              NPSA4                                                 12                2                       6.00                                                                 18.1                                                                  \+
  PSA 932[^d^](#tfn8-idr-1-051){ref-type="table-fn"}   NPSA5                                                 512               16                      ≥32.00                                                               16.7                                                                  \+
  PSA 776                                              NPSA6                                                 16                4                       4.00                                                                 34.3                                                                  \+
  PSA 784                                              NPSA7                                                 32                6                       5.33                                                                 2.6                                                                   --
  PSA 831                                              NPSA8                                                 16                6                       2.67                                                                 0.7                                                                   --

**Abbreviations:** CAZ, ceftazidime; FEP, cefepime; MIC, minimum inhibitory concentration; PFGE, pulsed-field gel electrophoresis.

**Notes:**

Isolates with clonal relations were grouped and separated by thinner line;

Specific mRNAs were quantified by real-time PCR after retrotranscription. Values are means of two independent determinations and are expressed relative to PAO1, which was set at 1.0;

*mexY* overexpression is indicated by a + sign;

Experimentally determined cefepime MIC \> 256 μg/ml; for calculation purposes, the value of 512 was utilized.
